Company news

Avacta Group PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

PFS Nearly Doubles with Faridoxorubicin Treatment

October 26, 2026

Avacta Highlights pre|CISION® Platform Data and Ongoing FOCUS-01 Trial Design with FAP-Exd (AVA6103)

October 23, 2026

Highlights pre|CISION® Platform Data

October 23, 2026

To Present on AVA6000 and AVA6103 at ESMO 2026

October 14, 2026

Notice of Interim Results Investor Meeting

October 12, 2026

Notice of Interim Results Investor Meeting

October 12, 2026

Results of Placing and Subscription

October 6, 2026

Capital Access Window - Avacta Group Plc

October 6, 2026

Results of Placing and Subscription

October 6, 2026

Proposed Fundraise to raise approximately £12.5m

October 5, 2026

Avacta Group plc: Interim Results for the Six Months to June 30, 2026, and Business Update

September 30, 2026

Capital Access Window - Avacta Group Plc

September 30, 2026

Capital Access Window

September 30, 2026

Interim Results for Six Months to June 30, 2026

September 30, 2026

pre|CISION® Platform Wins R&D Achievement Award

September 25, 2026

Further Demonstration of Potential of AVA6103

September 25, 2026

Avacta Group plc: The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer

September 25, 2026

Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial

September 16, 2026

Clinical Proof of Mechanism for preCISION Platform

September 16, 2026

Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committee

September 14, 2026

Mats Blom to Board as Chair of Audit Committee

September 14, 2026

Accelerated Payment Convertible Bond Installment

September 4, 2026

Share Option Awards to Management Team at Avacta

September 1, 2026

Avacta Group: Accelerated Amortized Payment of Convertible Bond Installment

July 9, 2026

Accelerated Amortized Payment of Bond Installment

July 9, 2026

Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors

July 8, 2026

Avacta Appoints Patrick Vink Deputy Chairman

July 8, 2026

Avacta Announces U.S. FDA Agreement on Pivotal Trial Design for AVA6000 in Patients with Salivary Gland Cancer

June 25, 2026

Platform-Validating Data with Faridoxorubicin

June 25, 2026

FDA Agreement on Pivotal Trial Design for AVA6000

June 25, 2026

Year-to-date business update ahead of AGM

June 22, 2026

Oversubscribed Strategic Equity Fundraise of £9m

June 5, 2026

Block Listing - Application to AIM

June 1, 2026

Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026

June 1, 2026

Clinical data on AVA6000 in salivary gland cancers

June 1, 2026

Annual Report and Accounts for the year ending 31 December 2025

May 29, 2026

Board Director Changes

May 29, 2026

Unaudited Preliminary Full Year 2025 Results

May 19, 2026

Notice of Preliminary Results and Presentation

May 13, 2026

Pre|CISION® payload release vs approved ADCs

May 6, 2026

Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026

May 6, 2026

Avacta data AACR underline AVA6103 profile

April 21, 2026

Christina Coughlin - In Vivo 2026 Rising Leader

April 14, 2026

Q1 2026 Business Update

April 9, 2026

Avacta Announces Science Day 2026

April 8, 2026

First patient treated in Phase 1 trial of AVA6103

March 31, 2026

Result of Oversubscribed Fundraise

March 27, 2026

Proposed Fundraise to raise approximately £10m

March 26, 2026

Issue of Equity

March 26, 2026

Presentations of pre|CISION® Platform Candidates

March 17, 2026

Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 16 decks. Every deck is listed under its year.